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Bronchial carcinoid tumor comprises 1 to 3% of lung neoplasms. The common 
age of onset is mainly post-puberty although atypical carcinoid tumors occur at 
ages 44 to 55. Carcinoid tumors cause two groups of symptoms in patients: 
symptoms due to obstruction and symptoms due to the production and release 
of active neuropeptides. Histologically, carcinoid tumors are categorized into 
two groups of typical and atypical while in terms of location of lesion, they are 
grouped into central and peripheral types. Differentiation between malignant 
and benign carcinoid tumors is based on presence or absence of metastasis.  
Bronchoscopy and endobronchial biopsy are the best diagnostic measures in 
these patients. Serologic evaluation and assessment of active metabolites in case 
of liver metastasis also help the diagnosis. Surgical resection is the treatment of 
choice for this condition.  
This report discusses a patient with carcinoid tumor who was receiving 
bronchodilator treatment for a couple of months because of chronic cough with 
possible diagnosis of asthma and had received several courses of antibiotic 
therapy with possible diagnosis of lung infection until he eventually developed 
bronchiectasis in the right lower lobe.  
In patients with chronic pulmonary symptoms especially with localized 
bronchiectasis, diagnostic bronchoscopy must be included in the diagnostic 
work-up to rule out intrabronchial lesions. 
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INTRODUCTION 
Carcinoid lung tumor is a rare pulmonary tumor with 
neuroendocrine cell (Kulchitsky cell) origin. These tumors 
are considered malignant due to their metastatic potential 
and have a wide spectrum of manifestations from a typical 
carcinoid to atypical neuroendocrine tumors and small cell 
lung cancer. Bronchial carcinoid tumor comprises 1 to 2% 
of all pulmonary tumors and approximately 20% of 
carcinoid tumors occur in the lungs (1, 2).  
Based on the type of cell, these tumors are 
microscopically divided into two types of typical and 
atypical types. In terms of location, these lesions are 
categorized  into  two   groups   of   peripheral  and  central  
 
types. The typical type is more prevalent, has a slower 
growth and less tendency to involve other organs. This 
type is approximately 4 times more common than the 
atypical type. However, the atypical type has a faster 
growth and higher tendency to involve other organs. 
About 75% of carcinoid tumors are of central type and 
usually involve the airway walls. 
Differentiation of the malignant and benign carcinoid 
tumors is based on presence or absence of metastasis rather 
than pathological findings because even in malignant 
carcinoids hyperchromatic pleomorphism or increased 
mitotic activity may be minimal or absent. Metastatic 
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potential in carcinoid tumors is more associated with the 
size of lesion and primary site of the tumor.  
Carcinoid tumor is the most common primary tumor of 
the lung in childhood. Pulmonary carcinoid tumors mainly 
have a post-pubertal onset and are usually seen at 45 years 
of age. However, patients with atypical carcinoid tumors 
are usually 10 years older than this age (3). A specific risk 
factor is usually not present and smoking is not among its 
risk factors. In the majority of studies, one-third to two-
third of patients are smokers. Atypical carcinoid patients 
have high cigarette consumption (4).  
 
Signs and symptoms:  
Proximal airway is usually the most commonly 
involved site by this tumor. Patients often experience 
obstructive symptoms and hemoptysis due to tumor 
hypervascularity. Patient complaints vary from cough, 
wheezing, hemoptysis and chest pain to recurrent 
segmental or lobar antibiotic-resistant pneumonia (5). 
About 25% of patients have peripheral involvement; which 
is mainly asymptomatic and is an incidental finding in 
radiological studies.  
Less than 5% of these tumors manifest symptoms due 
to the release of hormones by the tumor such as the 
carcinoid syndrome and metastasis which is indicative of 
low prevalence of liver metastasis in bronchial carcinoid 
tumor (6). 
 
Diagnostic workup: 
This tumor has the ability to produce and store active 
neuroamines and neuropeptides. Serum level of 
chromogranin A (CGA) increases in patients with 
bronchial carcinoid tumor; but, patients with non-
malignant conditions such as chronic renal failure, under 
treatment with proton pump inhibitors and those with 
chronic atrophic gastritis can also have high serum levels 
of CGA. Its measurement is non-specific for carcinoid 
tumor but is helpful for the follow up of the advanced 
disease and metastasis. Pulmonary carcinoids secrete less 
neuropeptides in comparison to intestinal carcinoids (7).  
Approximately 75% of bronchial carcinoids have 
abnormal chest X ray. The majority of these tumors 
manifest as 2-5 cm circular or round opacities or in the 
form of hilar masses. In case of bronchial obstruction, they 
manifest as atelectasis. Diagnosis is usually delayed and 
patients have often received several courses of antibiotic 
therapy due to pneumonia before reaching a definite 
diagnosis (8). 
Chest CT scan is obtained to better indicate the tumor 
and its location as well as the involvement of mediastinal 
lymph nodes. It also reveals the morphological 
characteristics of peripheral and central masses. CT scan 
sensitivity is very high for mediastinal and hilar nodes but 
its specificity is less than 45% (9).  
About 80% of carcinoid tumors have somatostatin 
receptors and are detected with radionuclide imaging 
using the somatostatin analog (octreotide) ( somatostatin 
receptor scintigraphy). However, use of this imaging 
technique has been limited considering its false positive 
results in other conditions such as tumors, granulomas and 
autoimmune diseases. When liver metastasis is suspected, 
use of abdominal CT scan or somatostatin scan provide 
favorable sensitivity and specificity and are optimal for 
detection of carcinoid metastasis (10).  
About 75% of bronchial carcinoids are of central type 
and bronchoscopically accessible for biopsy. For definite 
diagnosis, endobronchial biopsy needs to be carried out.  
 
Prognosis  
Typical carcinoid tumors have a good prognosis and 
their 5-year survival rate is 87-100%. Atypical carcinoid 
tumors have higher tendency for metastasis and their 5-
year survival rate varies from 30-90%. Chemotherapy and 
radiotherapy are effective for atypical stage-2 and 3 
surgically resected tumors but do not have the required 
efficacy for typical types (11).  
 
Treatment  
Bronchoscopic resection can be done for intrabronchial 
polypoid tumors. Surgical resection is the treatment of 
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choice for all patients given that their physiological 
condition allows it. The goal of treatment is complete 
resection of tumor along with the preservation of optimal 
functional lung capacity. Type of surgical procedure and 
extent of resection depend on tumor location (12, 13). 
Role of post-surgical adjuvant chemotherapy has not 
been very well documented and the majority of authors do 
not agree on post-surgical chemotherapy for typical 
carcinoid tumors. However, chemotherapy and 
radiotherapy are performed post-operatively in patients 
with stage II and III atypical carcinoid tumor.  
 
CASE SUMMARIES 
Our patient was a 20 year-old male with a history of 
asthma since three years earlier receiving several 
treatments during this time period. The patient developed 
severe productive coughs 4 days before hospitalization. He 
also complained of chest pain and wheezing. He 
mentioned no history of night sweat and had 2 
hospitalizations in the past 6 months due to low-grade 
fever and productive cough. The patient mentioned weight 
loss of about 4 kg during the past 6 months. He had no 
history of smoking with frequent hospitalizations 
following dyspnea attacks and exacerbation of coughs. He 
also had hospital stay due to lung infection. No history of 
diarrhea was recalled.  
The patient also mentioned the use of Seretide, 
cromolyn sodium, theophylline and Montelukast inhalers. 
Family history was negative for allergic and pulmonary 
diseases. His blood pressure was 110/70 mmHg, heart rate 
80/min, body temperature 38.9˚C, respiratory rate 22/min 
and arterial oxygen saturation rate was 92%. 
On physical examination, the patient had normal head 
and neck, normal cardiac examination and thoracic shape 
and symmetric movements along with reduced resonance 
in the lower half of the right lung. Mild and disseminated 
wheezing along with reduced pulmonary sounds were 
evident over the right lung. Examination of other organs 
revealed no specific findings. Clubbing was not present. 
The patient was hospitalized with a suspected diagnosis of 
pneumonia, bronchiectasis and asthma. 
During hospitalization, supportive therapy and 
bronchodilator treatment were administered for the patient 
based on his complaints. On chest X ray, air space lesions 
were observed in the inferior zone of the right lung and CT 
scan was requested for the patient.  
At 3 days post-hospitalization, the patient developed 
hemoptysis which was continued during the 4th and 5th 
days. Lung CT scan was indicative of bronchiectasis in the 
inferior zone of the right lung (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Lung CT-scan of patient. 
 
Considering the prolongation of hemoptysis and 
localized bronchiectasis in the inferior half of the right 
lung, the patient became a candidate for bronchoscopy. 
During bronchoscopy, a hypervascular pink mass was 
observed in the right main bronchus. A biopsy was 
obtained from this mass and sent to the pathology 
laboratory. The bronchial biopsy result revealed central 
typical bronchial carcinoid tumor. Patient’s 
bronchoalveolar lavage was reported negative for acid-fast 
bacilli. A consultation with a thoracic surgeon was 
requested and at day 14 post-hospitalization, the patient 
underwent inferior and middle lobectomy along with 
dissection of regional lymph nodes. No sign of mediastinal 
lymph node involvement was reported in patient’s 
Ghobadi  H, et al.   59 
Tanaffos 2013; 12(2): 56-60 
pathology report. One week after surgery the patient was 
discharged from the hospital in good general condition 
without respiratory problem. At 6 months follow up, the 
patient had no pulmonary symptoms and was in good 
general condition. No sign of tumor recurrence was noted.  
 
DISCUSSION 
Asthma is a pulmonary disease with an increasing 
prevalence during the past few decades. It is characterized 
by symptoms of dyspnea, cough and heaviness in the 
chest. However, none of the mentioned symptoms are 
specific for asthma and their presence alone is not 
indicative of this condition. On physical examination of 
asthmatic patients expiratory wheezing is present. 
However, this physical finding is not specific for asthma 
either and there are some differential diagnoses that need 
to be evaluated. Asthmatic patients experience airway 
remodeling which may be seen in other pulmonary 
diseases as well. Spirometry for detection of airway 
obstruction is necessary in asthmatic patients for diagnosis 
of this condition and determining its severity. This 
technique is not asthma-specific either and other 
differential diagnoses have to be considered as well.   
In patients with asthma attacks, chest X ray is normal 
although hyperinflation is seen in some cases. In all 
patients presenting for the first time with coughs and 
dyspnea, chest X ray is indicated due to the presence of 
thoracic symptoms. In our patient, considering the non-
specificity of pulmonary symptoms and history of several 
hospitalizations due to the exacerbation of symptoms and 
recurrence of disease, there was no sufficient data for 
definite diagnosis of asthma and complementary 
evaluations had to be performed. On the other hand, 
considering the abnormal radiography, and presence of 
air-space lesions at the lung bases, these findings did not 
correspond with asthma and other differential diagnoses 
had to be suggested and evaluated. However, our patient 
was symptomatic for a couple of years but no 
complementary evaluation was performed for him. 
Our patient had several hospitalizations with history of 
antibiotic therapy which reveals that the diagnosis of 
recurrent pneumonia had been probably suggested for 
him. In this situation, differential diagnoses of pneumonia 
should have been suggested and systematic assessment 
should have been done for the patient. Various conditions 
are included in differential diagnoses of patients who 
receive a complete course of antibiotic therapy but do not 
respond to it. A complete evaluation including physical 
examination, paraclinical assessments, and pulmonary 
imaging studies need to be performed for the patient. Two 
series of etiologic factors (infectious causes and non-
infectious causes) have to be considered in these patients.  
Of the non-infectious causes, neoplastic diseases are 
among the main differential diagnoses and have to be 
thoroughly investigated. In our case, no such evaluation 
was carried out during the several years that the patient 
was symptomatic. 
Considering the mentioned findings, presence of 
recurrent symptoms, history of several courses of antibiotic 
therapy and no recovery, presence of lesions on chest X ray 
and hemoptysis, our patient underwent further 
assessment. Bronchoscopy is the principal diagnostic 
measure in these patients considering local bronchiectasis. 
In our patient, bronchoscopy confirmed the presence of an 
obstructive mass. The intratracheal lesion was biopsied 
and the diagnosis of carcinoid tumor was 
histopathologically confirmed. 
The most common sign and symptom of carcinoid 
tumor are chronic cough and hemoptysis (18-35%), 
respectively and both were present in our patient. The 
most frequent finding in these symptomatic patients is a 
chronic obstructive mass which was observed in our 
patient. However, many of these patients are 
asymptomatic and the tumor is an incidental finding on 
chest x ray or CT-scan requested for another reason (5). 
 
CONCLUSION 
As there are no specific signs, symptoms or findings for 
asthma, a chest x ray is recommended for all patients 
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suspected of asthma and in case of presence of abnormal 
clinical findings, other differential diagnoses have to be 
considered. A systematic evaluation needs to be carried 
out as well. Also, in patients with recurrent pneumonia 
that have received several courses of antibiotic therapy 
with no recovery, obstructive lesions should be considered 
and diagnostic bronchoscopy has to be performed. In 
patients with localized bronchiectasis, intrabronchial local 
lesions should also be considered and thus, bronchoscopy 
must be necessarily performed for them. 
Carcinoid tumors are among the less prevalent 
pulmonary tumors but attention should be paid to less 
common pulmonary conditions in patients with 
pulmonary symptoms in order to achieve an in-time 
diagnosis and prevent further debilitation in these patients. 
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